Experience

Changchun GeneScience Pharmaceutical Co., Ltd.
• China
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• Deputy General Manager of Oncology BU, Head of Business Development & Strategic Planning

  • Jul 2023 - Present


Rona Therapeutics

• China
• Biotechnology Research
• 1 - 100 Employee

• Vice President of Business Development and Strategy

  • Nov 2022 - Jul 2023

  - Lead business development and alliance management, including technical platform and products license in/out, co-discovery and etc. - Responsible for investor relationship and fundraising activities - Portfolio management for Rona pipeline - Lead business development and alliance management, including technical platform and products license in/out, co-discovery and etc. - Responsible for investor relationship and fundraising activities - Portfolio management for Rona pipeline



Everest Medicines

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• VP, Strategic Planning & Operation

  • Jun 2021 - Nov 2022

  - Assist CCO to establish full-fledged commercial organization from 0 to 1, and build overall strategic framework - Develop and formalize the strategic planning process (including budgeting, annual brand planning) and operating procedures for Commercial Organization, leading Strategic Planning & Operation team - Identify later stage BD projects, CSO opportunities, lead commercial evaluations and develop mid-and-long term portfolio plan for all Everest Regions (Mainland China, Taiwan… Show more - Assist CCO to establish full-fledged commercial organization from 0 to 1, and build overall strategic framework - Develop and formalize the strategic planning process (including budgeting, annual brand planning) and operating procedures for Commercial Organization, leading Strategic Planning & Operation team - Identify later stage BD projects, CSO opportunities, lead commercial evaluations and develop mid-and-long term portfolio plan for all Everest Regions (Mainland China, Taiwan, South Korea, Singapore, Hong Kong etc.) - Establish launch readiness framework, co-lead launch strategy, act as PMO to drive launch readiness and mitigate risks - Scout & build strategic partnership; lead commercial innovation, particularly in access, channel, and digital marketing Show less - Assist CCO to establish full-fledged commercial organization from 0 to 1, and build overall strategic framework - Develop and formalize the strategic planning process (including budgeting, annual brand planning) and operating procedures for Commercial Organization, leading Strategic Planning & Operation team - Identify later stage BD projects, CSO opportunities, lead commercial evaluations and develop mid-and-long term portfolio plan for all Everest Regions (Mainland China, Taiwan… Show more - Assist CCO to establish full-fledged commercial organization from 0 to 1, and build overall strategic framework - Develop and formalize the strategic planning process (including budgeting, annual brand planning) and operating procedures for Commercial Organization, leading Strategic Planning & Operation team - Identify later stage BD projects, CSO opportunities, lead commercial evaluations and develop mid-and-long term portfolio plan for all Everest Regions (Mainland China, Taiwan, South Korea, Singapore, Hong Kong etc.) - Establish launch readiness framework, co-lead launch strategy, act as PMO to drive launch readiness and mitigate risks - Scout & build strategic partnership; lead commercial innovation, particularly in access, channel, and digital marketing Show less



Adicon Clinical Laboratories, Inc.

• Medical Practices
• 1 - 100 Employee

• Chief Marketing Officer

  • Oct 2020 - Jun 2021

  - Led team with 160+ HCs, scopes including central and local marketing, operation excellence, innovative business, customer service, and public affairs - Developed esoteric testing strategy to transform business, co-built a dedicated sales team, led over $200 Mn devices investment; Despite COVID-19 impact, esoteric business achieved 24% growth in Q1’21 vs. Q1’19 (or 82 % vs. Q1’20) - Established direct to consumer business, launched COVID-19 testing mini-program, developed 10+ on-line… Show more - Led team with 160+ HCs, scopes including central and local marketing, operation excellence, innovative business, customer service, and public affairs - Developed esoteric testing strategy to transform business, co-built a dedicated sales team, led over $200 Mn devices investment; Despite COVID-19 impact, esoteric business achieved 24% growth in Q1’21 vs. Q1’19 (or 82 % vs. Q1’20) - Established direct to consumer business, launched COVID-19 testing mini-program, developed 10+ on-line channel promotion partnerships, developed and launched self-testing HPV product Show less - Led team with 160+ HCs, scopes including central and local marketing, operation excellence, innovative business, customer service, and public affairs - Developed esoteric testing strategy to transform business, co-built a dedicated sales team, led over $200 Mn devices investment; Despite COVID-19 impact, esoteric business achieved 24% growth in Q1’21 vs. Q1’19 (or 82 % vs. Q1’20) - Established direct to consumer business, launched COVID-19 testing mini-program, developed 10+ on-line… Show more - Led team with 160+ HCs, scopes including central and local marketing, operation excellence, innovative business, customer service, and public affairs - Developed esoteric testing strategy to transform business, co-built a dedicated sales team, led over $200 Mn devices investment; Despite COVID-19 impact, esoteric business achieved 24% growth in Q1’21 vs. Q1’19 (or 82 % vs. Q1’20) - Established direct to consumer business, launched COVID-19 testing mini-program, developed 10+ on-line channel promotion partnerships, developed and launched self-testing HPV product Show less



Jiangsu Hengrui Medicine Co., Ltd.

• Medical Practices
• 1 - 100 Employee

• Marketing Director

  • Jun 2019 - Oct 2020

  - Led team with 20+ HCs and $5 Mn promotion budget, responsible for in market promotion and pipeline planning for HCC and GU portfolio (annual revenue ~ $330 Mn year of 2020), from new products to VBP products - Co-launched Camrelizumab and achieved highest market share within one year (5th entry of CIT, after two MNCs and two local biotech), launched 1st HCC cancer immunotherapy (Camrelizumab) in China in March 2020 - Built market insight team with strong analytical capabilities to… Show more - Led team with 20+ HCs and $5 Mn promotion budget, responsible for in market promotion and pipeline planning for HCC and GU portfolio (annual revenue ~ $330 Mn year of 2020), from new products to VBP products - Co-launched Camrelizumab and achieved highest market share within one year (5th entry of CIT, after two MNCs and two local biotech), launched 1st HCC cancer immunotherapy (Camrelizumab) in China in March 2020 - Built market insight team with strong analytical capabilities to support overall oncology portfolio Show less - Led team with 20+ HCs and $5 Mn promotion budget, responsible for in market promotion and pipeline planning for HCC and GU portfolio (annual revenue ~ $330 Mn year of 2020), from new products to VBP products - Co-launched Camrelizumab and achieved highest market share within one year (5th entry of CIT, after two MNCs and two local biotech), launched 1st HCC cancer immunotherapy (Camrelizumab) in China in March 2020 - Built market insight team with strong analytical capabilities to… Show more - Led team with 20+ HCs and $5 Mn promotion budget, responsible for in market promotion and pipeline planning for HCC and GU portfolio (annual revenue ~ $330 Mn year of 2020), from new products to VBP products - Co-launched Camrelizumab and achieved highest market share within one year (5th entry of CIT, after two MNCs and two local biotech), launched 1st HCC cancer immunotherapy (Camrelizumab) in China in March 2020 - Built market insight team with strong analytical capabilities to support overall oncology portfolio Show less



Roche

• Switzerland
• Biotechnology Research
• 700 & Above Employee

• Associate Marketing Direcotr, GI/GU/GYN

  • Nov 2018 - Jun 2019

  - Lead launch readiness for Tecentriq (PD-L1) +Avastin (Anti-VEGF) in 1L HCC, OC, and Avastin in rGBM

• Associate Marketing Director, Lung Cancer

  • May 2018 - Dec 2018

  - Led 2 direct reports and manage ~$3 mio promotion budget for Avastin lung cancer in respiratory, surgeon and radio oncology departments and manage Tarceva P&L, annual sales over $70 mio. Developed Avastin and Tarceva lung cancer mid-term strategy, and lead annual business & budget process - Initiated respiratory specific customer engagement programs to capture potential after Avastin NRDL listing, and delivered 20% R3 growth (Aug-Oct vs. May-Jul), highest among all Avastin indications and… Show more - Led 2 direct reports and manage ~$3 mio promotion budget for Avastin lung cancer in respiratory, surgeon and radio oncology departments and manage Tarceva P&L, annual sales over $70 mio. Developed Avastin and Tarceva lung cancer mid-term strategy, and lead annual business & budget process - Initiated respiratory specific customer engagement programs to capture potential after Avastin NRDL listing, and delivered 20% R3 growth (Aug-Oct vs. May-Jul), highest among all Avastin indications and departments - Designed and implemented innovative and digital campaigns, and turned around Tarceva performance from declining trend (1H’18) to positive trend (2H’18), and delivered over 40% YoY growth (YTD Nov’18)



Genentech

• United States
• Biotechnology Research
• 700 & Above Employee

• Sales, Xolair

  • Jun 2016 - Apr 2018

  - Co-manage a territory with Novartis partner, promote Xolair for Allergic Asthma and Chronic Idiopathic Urticaria, annual revenue ~ $15 mio (2017), covering Arkansas, Northern Louisiana, and Joplin, MO - Launched Pediatric Allergic Asthma indication in July 2016, leveraged the halo effect to drive overall growth, and delivered ~18% YOY volume growth (1H’17 vs. 1H’16) in Allergist, highest Allergist growth in the division

• Product Manager, Pulmozyme

  • Jun 2015 - May 2016

  - Reported to Strategic Market Lead, responsibilities include 3 year brand plan and 1 year tactic plan. Co-led design-thinking workshops with sales and cross-functional partners to generate 20+ innovative tactics as input for 2016 tactical plan. Led the development of one tactic to roll it out at 2016 NSM (<5 months from concept to deployment) - Executed strategy for new Cystic Fibrosis Market entrant by developing messages and deploying resources within one-month post approval. The… Show more - Reported to Strategic Market Lead, responsibilities include 3 year brand plan and 1 year tactic plan. Co-led design-thinking workshops with sales and cross-functional partners to generate 20+ innovative tactics as input for 2016 tactical plan. Led the development of one tactic to roll it out at 2016 NSM (<5 months from concept to deployment) - Executed strategy for new Cystic Fibrosis Market entrant by developing messages and deploying resources within one-month post approval. The strategy mitigated prescription discontinuation risk, and brand exceed sales target in 2015 (1.7% above goal with 4% demand growth)

• Sr. Strategic Planning Manager, BU2

  • Feb 2013 - May 2015

  - Led 2 direct reports to work with BU VP and MDs to develop strategic decisions on new product launch, line extension, positioning, access strategy and growth strategy (Avastin, Tarceva, MabThera, and Gazyva) - Developed China’s mid-term growth strategy with senior leadership, covering portfolio prioritization, resource allocation guidance and operation model implications. Proposed 15+ initiatives to accelerate organization transformation, with the potential of additional 3% growth on top… Show more - Led 2 direct reports to work with BU VP and MDs to develop strategic decisions on new product launch, line extension, positioning, access strategy and growth strategy (Avastin, Tarceva, MabThera, and Gazyva) - Developed China’s mid-term growth strategy with senior leadership, covering portfolio prioritization, resource allocation guidance and operation model implications. Proposed 15+ initiatives to accelerate organization transformation, with the potential of additional 3% growth on top line revenue ($50+ mio annually)

• Sr. SFE Manager (acting), Oncology Franchise

  • Jan 2014 - Jun 2014

  - Responsible for sales force effectiveness for both BU1 & BU2 (oncology BUs in Roche China), over 500 sales reps - Lead a team of 3 to provide strategic insights and operation support in sales force sizing, targeting, territory alignment, incentive scheme design & calculation, and monthly sales operation dashboardled a team of 4 in SFE to provide sales force structure, sizing, and alignment insights for all oncology products



ZS

• 1 - 100 Employee

• Consultant

  • Jul 2010 - Feb 2013

  - Led and delivered 30+ consulting projects, covering China healthcare markets, spanning from understanding treatment decision processes, forecasting, launch planning, commercial organization design, sales strategy and sales force effectiveness

• Analyst

  • Jul 2008 - Jul 2010

  - Focused on US healthcare market, provide management consulting service in sales and marketing to bio-tech companies in west coast